The DOI matches its Crossref record.
Current Drug Targets in Obesity Pharmacotherapy – A Review
Abstract
Obesity, an impending global pandemic, is not being effectively controlled by current measures such as lifestyle modifications, bariatric surgery or available medications. Its toll on health and economy compels us to look for more effective measures. Fortunately, the advances in biology and molecular technology have been in our favour for delineating new pathways in the pathophysiology of obesity and have led to subsequent development of new drug targets. Development of antiobesity drugs has often been riddled with problems in the past. Some of the recently approved drugs for pharmacotherapy of obesity have been lorcaserin, phentermine/topiramate and naltrexone/ bupropion combinations. Several promising new targets are currently being evaluated, such as amylin analogues (pramlintide, davalintide), leptin analogues (metreleptin), GLP-1 analogues (exenatide, liraglutide, TTP-054), MC4R agonists (RM-493), oxyntomodulin analogues, neuropeptide Y antagonists (velneperit), cannabinoid type-1 receptor blockers (AM-6545), MetAP2 inhibitors (beloranib), lipase inhibitors (cetilistat) and anti-obesity vaccines (ghrelin, somatostatin, Ad36). Many of these groups of drugs act as "satiety signals" while others act by antagonizing orexigenic signals, increasing fat utilisation and decreasing absorption of fats. Since these targets act through various pathways, the possibility of combined use of two or more classes of these drugs unlocks numerous therapeutic avenues. Hence, the dream of personalized management of obesity might be growing closer to reality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It acts as an appetite-suppressant by disrupting β-endorphin-mediated POMC auto-inhibition [10].”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [10]
Citations
Cited by
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
Obesity and insulin resistance: Pathophysiology and treatment
Tong, Y., Xu, S., Huang, L., & Chen, C. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2021.11.001 · Cited by 218
Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review
Tak, Y. J., & Lee, S. Y. (2021) · The World Journal of Men's Health · doi:10.5534/wjmh.200010 · Cited by 184
“Other co-administered medications have been investigated to elucidate their long-term efficacy and adverse events [15,16].”
BackgroundBriguglio, M., Vitale, J. A., Galentino, R., Banfi, G., Dina, C. Z., Bona, A. R., Panzica, G., Porta, M., Dell’Osso, B. M., & Glick, I. D. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s229206 · Cited by 119
Pediatric obesity: Current concepts
Greydanus, D. E., Agana, M. G., Kamboj, M. K., Shebrain, S., Soares, N. S., Eke, R., & Patel, D. R. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2017.12.001 · Cited by 107
Metadata
- Authors
- Bhat, S. P., & Sharma, A.
- Affiliations
- Aligarh Muslim University (IN)
- Corresponding author
- Bhat, Sangeeta P.
- Sharma, Arun
- ORCID
- Sharma, Arun
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2017-05-04
- Volume
- 18
- Issue
- 8
- Pages
- 983-993
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2594133229
- Cited by
- 60
- References
- 0
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 8 · 2023: 4 · 2022: 8 · 2021: 6 · 2020: 11 · 2019: 9 · 2018: 7 · 2017: 3
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity pharmacotherapy, anti-obesity drugs, therapeutic target, lorcaserin, phentermine/topiramate, naltrexone/bupropion, amylin analogues, GLP-1 receptor agonists, MC4R agonist, MetAP2 inhibitors, lipase inhibitors, satiety signals, combination therapy
- MeSH terms
- Drug Therapy, Combination, Humans, Obesity, Signal Transduction, Anti-Obesity Agents, Precision Medicine, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current Drug Targets in Obesity Pharmacotherapy – A Review. https://app.cochat.ai/papers/10.2174/1389450118666170227153940
- The paper
- Bhat, S. P., & Sharma, A. (2017). Current Drug Targets in Obesity Pharmacotherapy – A Review. Current Drug Targets. https://doi.org/10.2174/1389450118666170227153940
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.